AstraZeneca’s immunotherapies Imfinzi and Imjudo have been approved in Japan for the treatment of three cancer types: advanced liver, biliary tract and lung. The approvals authorize Imfinzi in combination with Imjudo for the treatment of adult patients with unresectable hepatocellular carcinoma, or HCC, and for the treatment of adult patients with unresectable, advanced or recurrent non-small cell lung cancer, or NSCLC, in combination with chemotherapy. Imfinzi was also authorized for the treatment of adult patients with unresectable HCC as monotherapy and for the treatment of adult patients with curatively unresectable biliary tract cancer, or BTC, in combination with chemotherapy. The concurrent approvals by the Japanese Ministry of Health, Labour, and Welfare are based on positive results from the HIMALAYA and TOPAZ-1 Phase III trials, each published in the New England Journal of Medicine Evidence and the POSEIDON Phase III trial, published in the Journal of Clinical Oncology.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca’s Lynparza approved in E.U. as first line treatment in mCRPC
- Merck, AstraZeneca: LYNPARZA/abiraterone and prednisone combo approved in EU
- AstraZeneca’s Imfinzi+chemotherapy approved in E.U. in BTC patients
- AstraZeneca, G42 Healthcare enter strategic partnership agreement
- AstraZeneca says PEARL trial didn’t achieve statistical significance on endpoint
